|1.||Tomlinson, Brian: 3 articles (10/2010 - 10/2006)|
|2.||Falutz, Julian: 2 articles (01/2015 - 06/2011)|
|3.||Dhillon, Sohita: 2 articles (12/2011 - 05/2011)|
|4.||Prous, J R: 2 articles (06/2005 - 06/2004)|
|5.||Rabasseda, X: 2 articles (06/2005 - 06/2004)|
|6.||Hayward, Brooke: 1 article (01/2015)|
|7.||Mamputu, Jean-Claude: 1 article (01/2015)|
|8.||Mangili, Alexandra: 1 article (01/2015)|
|9.||Stepanians, Miganush: 1 article (01/2015)|
|10.||Bhangoo, Amrit: 1 article (06/2013)|
03/01/2009 - "A multicenter, randomized, placebo-controlled, Phase III clinical trial suggested that tesamorelin might be a beneficial treatment strategy for HIV-related lipodystrophy with a good safety profile and a positive effect on reducing visceral fat. "
10/01/2010 - "Additional long-term outcome trials are required to determine the long-term safety of tesamorelin and to evaluate whether this agent, or other GRF agonists, could reduce the cardiovascular risk associated with lipodystrophy-related metabolic complications and help to maintain a more normal distribution of body fat."
04/01/2011 - "Tesamorelin: A hope for ART-induced lipodystrophy."
12/15/2010 - "FDA approves tesamorelin for HIV-related lipodystrophy."
03/01/2009 - "This article reviews the development of tesamorelin and its purported role in HIV-related lipodystrophy and other potential indications. "
|2.||HIV-Associated Lipodystrophy Syndrome
02/01/2012 - "Tesamorelin is effective in improving visceral adiposity and body image in patients with HIV-associated lipodystrophy over 26-52 weeks of treatment. "
02/01/2012 - "All studies relevant to the evaluation of efficacy and safety of tesamorelin in the management of HIV-associated lipodystrophy were included, with a focus on trials completed in humans. "
06/01/2013 - "The GHRH analog-Tesamorelin is the only treatment option, which is FDA approved for use in reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. "
12/01/2011 - "Although long-term clinical experience is needed to further assess the benefits and risks of therapy, current evidence suggests that tesamorelin may be useful for reducing visceral adiposity in patients with HIV-associated lipodystrophy, thereby potentially improving self image."
12/01/2011 - "Spotlight on tesamorelin in HIV-associated lipodystrophy."
|3.||HIV Infections (HIV Infection)
10/01/2010 - "The most promising GRF agonist in development is tesamorelin (EMD Serono/Theratechnologies), which has exhibited efficacy for the treatment of excess visceral adipose tissue in patients with HIV infection in two recent phase III, randomized, placebo-controlled clinical trials. "
02/01/2012 - "Tesamorelin provides a useful treatment option for management of patients with significant lipodystrophy related to HIV infection."
02/01/2012 - "To evaluate the efficacy and safety of tesamorelin, a growth hormone releasing factor analogue approved by the Food and Drug Administration in November 2010 for the treatment of lipodystrophy associated with HIV infection. "
|4.||Human Influenza (Influenza)
|5.||Body Weight (Weight, Body)
01/01/2007 - "Plasma growth hormone and insulin-like growth factor-1 (IGF-1) markedly increased in pigs, rats and dogs after daily repeat intravenous or subcutaneous injections of TH9507 at doses up to 600 microg/kg. Subchronic toxicity studies in rats and dogs with TH9507 treatment for up to 4 months showed a significant, but not dose-related, increase in body weight gain associated with increased biomarker response. "
|1.||Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)
|4.||Growth Hormone (Somatotropin)
|5.||Brain Natriuretic Peptide (Natrecor)
|10.||Sodium Oxybate (gamma Hydroxybutyrate)